AbbVie Inc. is trading at $225.00 (+3.6%) in pre-market after its ovarian cancer drug, Elahere, was approved for use by the NHS in England.
- The approval marks the first new treatment for this specific type of advanced, platinum-resistant ovarian cancer in the UK in about 20 years.
- This decision provides a new targeted option for patients with limited alternatives and strengthens AbbVie's oncology portfolio.
- The positive company-specific news comes as the broader healthcare sector has also seen increased investor interest.